These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 10136601)

  • 21. Drug-use review program for concurrent histamine H2-receptor antagonist-sucralfate therapy.
    Kane MP; Briceland LL; Garris RE; Favreau BN
    Am J Hosp Pharm; 1990 Sep; 47(9):2007-10. PubMed ID: 1977317
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug utilization & therapeutic intervention programs: pharmacy services that pay for themselves.
    Condron JH; Mann JL
    Can J Hosp Pharm; 1994 Oct; 47(5):203-8. PubMed ID: 10137698
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost considerations of intravenously administered histamine2-receptor antagonists.
    Nolly RJ; Skoutakis VA
    DICP; 1989 Oct; 23(10 Suppl):S23-8. PubMed ID: 2573206
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The use of intravenous H2-receptor antagonists in a tertiary care hospital.
    Dettmer RM; Riley TH; Byfield F; Green PH
    Am J Gastroenterol; 1999 Dec; 94(12):3473-7. PubMed ID: 10606306
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiulcer therapy: an exercise in formulary management.
    Foulke GE; Siepler J
    J Clin Gastroenterol; 1990; 12 Suppl 2():S64-8. PubMed ID: 1978846
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Change in prescribing patterns of intravenous histamine2-receptor antagonists results in significant cost savings without adversely affecting patient care.
    Fudge KA; Moore KA; Schneider DN; Sherrin TP; Wellman GS
    Ann Pharmacother; 1993 Feb; 27(2):232-7. PubMed ID: 8094986
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Experience with a two-tiered therapeutic interchange policy.
    Rich DS
    Am J Hosp Pharm; 1989 Sep; 46(9):1792-8. PubMed ID: 2572167
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Shifting physician prescribing to a preferred histamine-2-receptor antagonist. Effects of a multifactorial intervention in a mixed-model health maintenance organization.
    Brufsky JW; Ross-Degnan D; Calabrese D; Gao X; Soumerai SB
    Med Care; 1998 Mar; 36(3):321-32. PubMed ID: 9520957
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacist adjustment of H2-receptor antagonist dosage to meet medical staff-approved criteria.
    Malcolm KE; Griffin CR; Bennett TA; Robertson LM
    Am J Hosp Pharm; 1994 Sep; 51(17):2152-4. PubMed ID: 7985692
    [No Abstract]   [Full Text] [Related]  

  • 30. Multi-purpose evaluation of H2-antagonist usage.
    Gianarkis D
    Hosp Formul; 1992 May; 27(5):527-30, 532. PubMed ID: 10117769
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gastroesophageal reflux and histamine2 antagonists.
    Bell SG
    Neonatal Netw; 2003; 22(2):53-7. PubMed ID: 12696725
    [No Abstract]   [Full Text] [Related]  

  • 32. The impact of China's retail drug price control policy on hospital expenditures: a case study in two Shandong hospitals.
    Meng Q; Cheng G; Silver L; Sun X; Rehnberg C; Tomson G
    Health Policy Plan; 2005 May; 20(3):185-96. PubMed ID: 15840634
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Histamine type 2-receptor antagonists and cancer immunotherapy.
    Smith T
    Compr Ther; 1990 Jan; 16(1):8-13. PubMed ID: 1967999
    [No Abstract]   [Full Text] [Related]  

  • 34. A vancomycin drug use evaluation and economic analysis in a cancer treatment centre.
    Dranitsaris G; Pilla NJ; McGreer A
    Can J Hosp Pharm; 1994 Apr; 47(2):59-64. PubMed ID: 10134128
    [TBL] [Abstract][Full Text] [Related]  

  • 35. G-CSF (Granulocyte Colony-Stimulating Factor): follow-up and use in a French University hospital.
    Furet I; Closson V; Madelaine I; Faure P
    Can J Hosp Pharm; 1995 Apr; 48(2):90-7. PubMed ID: 10142843
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A cost comparison of Canadian and U.S. hospital pharmacy departments.
    Weil TP
    Hosp Pharm; 1994 Jan; 29(1):15-7, 20-3. PubMed ID: 10131492
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of histamine2-antagonists for the treatment of verruca vulgaris.
    Fit KE; Williams PC
    Ann Pharmacother; 2007 Jul; 41(7):1222-6. PubMed ID: 17535844
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug usage evaluation: H2-receptor antagonist use in 30 hospitals.
    Kowalsky SF; Hamilton RA; Figge HL
    Hosp Formul; 1991 Sep; 26(9):725-6, 732, 734-6 passim. PubMed ID: 10114004
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Switching the histamine H2 receptor antagonist famotidine to nonprescription status in Canada. An economic evaluation.
    Tasch RF; Goeree R; Henke CJ; O'Brien BJ
    Pharmacoeconomics; 1996 Jan; 9(1):61-75. PubMed ID: 10160088
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adjusting dosage intervals of intermittent intravenous ranitidine according to creatinine clearance: a cost-minimization analysis.
    Connelly JF
    Hosp Pharm; 1994 Nov; 29(11):992, 996-8, 1001. PubMed ID: 10138581
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.